C4 Therapeutics, Inc. (CCCC)
$1.22
Rating:
Recommendation:
-
| Symbol | CCCC |
|---|---|
| Price | $1.22 |
| Beta | 2.235 |
| Volume Avg. | 0.54M |
| Market Cap | 60.123M |
| Shares () | - |
| 52 Week Range | 1.06-9.41 |
| 1y Target Est | - |
| DCF Unlevered | CCCC DCF -> | |
|---|---|---|
| DCF Levered | CCCC LDCF -> | |
| ROE | -53.11% | Strong Sell |
| ROA | -39.93% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 33.41% | Neutral |
| P/E | -0.44 | Neutral |
| P/B | 0.28 | Neutral |
Latest CCCC news
About
Download (Excel)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.